R. Nolan Townsend, CEO, LEXEO Therapeutics

At LEXEO, Townsend is leading a multi-pronged gene therapy pipeline tackling several neurodegenerative diseases, including Batten disease, Friedreich’s ataxia, and Alzheimer’s disease. The approach to treating Alzheimer’s is a fascinating one, targeting apolipoprotein E (APOE), which serves as the major transporter of cholesterol in the brain. Variants in this gene on chromosome 19, specifically APOE4, are strongly associated with increased risk for Alzheimer’s disease . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articlePart III: Hank Zetterberg, MD, PhD, Offers Insights into Alzheimer’s Biomarkers
Next articlePart I: MassGeneral’s Rudy Tanzi, PhD, Shares New Genetic Findings on Alzheimer’s